On January 5, 2023 PDX Pharma reported that its proprietary platform (Pdx-NP) utilizes polymer-modified mesoporous silica nanoparticles and can effectively co-deliver a plethora of therapeutic modalities while maintaining a small size, suitable for infusion and tumor accumulation (Press release, PDX Pharmaceuticals, JAN 5, 2023, View Source [SID1234625907]). ARAC-02, one of our leading candidates, targets PD-L1, PLK1, and TLR9, and has the ability to simultaneously kill cancer while also inducing a potent anti-tumor immune response. ARAC-02 development won a $2.3M fast track SBIR award from the NCI with a rare perfect score in September 2021. In December 2022, ARAC-02 was selected into the NCL’s Assay Cascade Characterization Program, during which its physicochemical properties and in vitro and in vivo compatibility (immunology, pharmacology, and toxicology) will be characterized at no cost using a standardized assay cascade developed in collaboration with the FDA and NIST. This program will directly support our IND enabling studies toward the clinical adoption of ARAC-02.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!